FDG Uptake, Tumour characteristics and therapy response

a review

Timothy Andrew Davies Smith

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

The use of FDG-PET imaging in tumour detection is now well established. Many studies have suggested that changes in the uptake of FDG predict tumour response to therapy and that further clinical information regarding tumour grade and proliferative status may also be derived from FDG-uptake scans. More studies are required to verify the role of FDG-PET in patient management. Upregulation of hexokinase and glucose transporters, especially Glut-1, and downregulation of glucose-6-phosphatase are frequently associated with transformation. The extent of these changes has been related to both differentiation and proliferation largely corresponding with FDG-uptake studies.
Original languageEnglish
Pages (from-to)97-105
Number of pages9
JournalNuclear Medicine Communications
Volume19
Issue number2
Publication statusPublished - 1 Jan 1998

Fingerprint

Glucose-6-Phosphatase
Neoplasms
Hexokinase
Facilitative Glucose Transport Proteins
Up-Regulation
Therapeutics
Down-Regulation

Cite this

FDG Uptake, Tumour characteristics and therapy response : a review. / Smith, Timothy Andrew Davies.

In: Nuclear Medicine Communications, Vol. 19, No. 2, 01.01.1998, p. 97-105.

Research output: Contribution to journalArticle

Smith, Timothy Andrew Davies. / FDG Uptake, Tumour characteristics and therapy response : a review. In: Nuclear Medicine Communications. 1998 ; Vol. 19, No. 2. pp. 97-105.
@article{b980ab2cd3ac4b258771a7f61abf8a52,
title = "FDG Uptake, Tumour characteristics and therapy response: a review",
abstract = "The use of FDG-PET imaging in tumour detection is now well established. Many studies have suggested that changes in the uptake of FDG predict tumour response to therapy and that further clinical information regarding tumour grade and proliferative status may also be derived from FDG-uptake scans. More studies are required to verify the role of FDG-PET in patient management. Upregulation of hexokinase and glucose transporters, especially Glut-1, and downregulation of glucose-6-phosphatase are frequently associated with transformation. The extent of these changes has been related to both differentiation and proliferation largely corresponding with FDG-uptake studies.",
author = "Smith, {Timothy Andrew Davies}",
year = "1998",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "97--105",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - FDG Uptake, Tumour characteristics and therapy response

T2 - a review

AU - Smith, Timothy Andrew Davies

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The use of FDG-PET imaging in tumour detection is now well established. Many studies have suggested that changes in the uptake of FDG predict tumour response to therapy and that further clinical information regarding tumour grade and proliferative status may also be derived from FDG-uptake scans. More studies are required to verify the role of FDG-PET in patient management. Upregulation of hexokinase and glucose transporters, especially Glut-1, and downregulation of glucose-6-phosphatase are frequently associated with transformation. The extent of these changes has been related to both differentiation and proliferation largely corresponding with FDG-uptake studies.

AB - The use of FDG-PET imaging in tumour detection is now well established. Many studies have suggested that changes in the uptake of FDG predict tumour response to therapy and that further clinical information regarding tumour grade and proliferative status may also be derived from FDG-uptake scans. More studies are required to verify the role of FDG-PET in patient management. Upregulation of hexokinase and glucose transporters, especially Glut-1, and downregulation of glucose-6-phosphatase are frequently associated with transformation. The extent of these changes has been related to both differentiation and proliferation largely corresponding with FDG-uptake studies.

M3 - Article

VL - 19

SP - 97

EP - 105

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 2

ER -